• Molecular NameDoxorubicin
  • Synonymdoxorubicin; Doxorubicin HCl; Doxorubicin Hydrochloride; Doxorubicina [INN-Spanish]; Doxorubicine [INN-French]; Doxorubicinum [INN-Latin]
  • Weight543.525
  • Drugbank_IDDB00997
  • ACS_NO23214-92-8
  • Show 3D model
  • LogP (experiment)0.455
  • LogP (predicted, AB/LogP v2.0)0.47
  • pka8.2, 10.2
  • LogD (pH=7, predicted)-0.63
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-4.68
  • LogSw (predicted, AB/LogsW2.0)0.49
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors7
  • No.of HBond Acceptors12
  • No.of Rotatable Bonds5
  • TPSA206.07
  • StatusFDA approved
  • AdministrationIntravenous
  • PharmacologyA drug used in cancer chemotherapy. It is an anthracycline antibiotic, closely related to the natural product daunomycin, and like all anthracyclines it works by intercalating DNA. It is commonly used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas.
  • Absorption_value5.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability5.0
  • Protein binding76.0
  • Volume of distribution (VD)13
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmCYP3A4. The major metabolite of doxorubicin is doxorubicinol. Both undergo enzymatic reduction at the 7 position and cleavage of the daunosamine sugar yielding aglycones which are accompanied by free radical formation, the local production of which may contribute to the cardiotoxic activity of doxorubicin.
  • Half life26 h (Prolonged when plasma bilirubin concentration is elevated; undergoes biliary excretion)
  • ExcretionBiliary and fecal
  • Urinary Excretion<7
  • Clerance666 +/- 339 ml/min/(m2)
  • ToxicityWhen the cumulative dose of doxorubicin reaches 550 mg/m??, the risks of developing cardiac side effects, including congestive heart failure, dilated cardiomyopathy, and death, dramatically increase.
  • LD50 (rat)LD50=21800 ug/kg (rat, subcutaneous)
  • LD50 (mouse)N/A